Bayh-Dole Act

The Bayh-Dole Act is the federal law — Public Law 96-517, enacted December 12, 1980, and codified at 35 U.S.C. §§ 200–212 — that allows universities, small businesses, and nonprofit institutions to retain title (ownership) to patentable inventions made with federal research funding, rather than the government automatically taking title. In exchange, the recipient institution (the “contractor,” in the statute’s language) takes on a defined set of obligations: disclosing each invention to the funding agency, electing whether to keep title within a set window, filing a patent application if it does, and accepting the government’s retained rights — including march-in rights and a preference for U.S. manufacturing. It is the single piece of federal law that created the legal basis for the modern university technology transfer office.

The Act is named for its Senate sponsors, Birch Bayh of Indiana and Bob Dole of Kansas, and was formally titled the Patent and Trademark Law Amendments Act of 1980. Before it passed, federal agencies each ran their own, inconsistent invention-rights policies, and the government itself typically held title to inventions arising from federally funded research; the legislative record behind Bayh-Dole cited roughly 28,000 government-owned patents at the time, of which fewer than 5% had ever been licensed for commercial use. Bayh-Dole replaced that fragmented, government-title default with a single, uniform statutory framework.

What makes something an instance of Bayh-Dole

Bayh-Dole applies specifically to a “subject invention”: any invention conceived or first actually reduced to practice in the performance of work under a federal funding agreement (a grant, cooperative agreement, or contract), where the recipient is a university, other nonprofit organization, or a small business as defined under the Small Business Act. (A 1983 presidential memorandum, and subsequent agency policy, extended equivalent treatment to large-business federal contractors in most cases, though the statute’s own text is written around the small-business/nonprofit distinction.) Three elements have to be true simultaneously for the Act’s framework to govern a given invention:

• Federal funding agreement. The research that produced the invention was performed under a grant, contract, or cooperative agreement with a federal agency — not institutional funds, industry sponsorship alone, or a state grant.
• Eligible recipient. The organization holding the award is a university, other nonprofit, or a small business (the categories the statute names directly).
• Invention made “in the performance of” the award. The conception or first actual reduction to practice occurred as part of the funded work, not incidentally by someone who happened to also hold an unrelated federal award.

Where all three hold, the institution — not the individual inventor, and not the government by default — is the party the statute gives the first opportunity to retain title, provided it meets the obligations below.

What Bayh-Dole requires in exchange for retaining title

Title isn’t unconditional. 35 U.S.C. § 202 and its implementing regulation, 37 CFR Part 401, set out the core compliance sequence every recipient institution has to follow:

1. Disclosure. The contractor must disclose each subject invention to the funding federal agency within a reasonable time after it becomes known to the personnel responsible for patent matters — in practice, this is almost always routed through the iEdison system. If the institution fails to disclose in time, the government may take title to that invention outright.
2. Election of title. The contractor has up to two years from disclosure to elect, in writing, whether it will retain title (that window can be shortened by the agency to as little as 60 days before a statutory bar under 35 U.S.C. § 102 would otherwise destroy patentability — e.g. an imminent public disclosure or sale). If the institution doesn’t elect within the window, title reverts to the government.
3. Patent filing. Once title is elected, the institution must file a patent application — typically a provisional application followed by a nonprovisional within the statutory conversion period — and diligently prosecute it.
4. Government-support statement. Any patent application filed on a subject invention must include a statement acknowledging federal support and the government’s rights, per 37 CFR § 401.14(f)(4).
5. Utilization reporting. The funding agency may request periodic reports (no more than annually) on the invention’s development status, date of first commercial sale, and royalties received — also filed through iEdison.

Failing to meet any of these deadlines is one of the most common ways an institution loses rights it would otherwise have kept — see CASRAI’s iEdison guide for the exact deadline structure under 37 CFR § 401.14.

The government’s retained rights: march-in and beyond

Bayh-Dole gives the funding agency several rights it can exercise even after the institution has retained title:

• Government-use license. Under 35 U.S.C. § 202(c)(4), the government automatically retains a nonexclusive, nontransferable, royalty-free license to practice the invention itself, worldwide, regardless of who holds title.
• March-in rights. Under 35 U.S.C. § 203, a federal agency can require the title-holder to grant a license to a responsible third party — on reasonable terms, and nonexclusive, partially exclusive, or exclusive as the situation requires — if any of four conditions apply: the holder hasn’t taken, and isn’t expected to take within a reasonable time, effective steps to achieve practical application of the invention; action is necessary to alleviate health or safety needs not reasonably satisfied by the holder; action is necessary to meet public-use requirements specified by federal regulation and not reasonably satisfied; or the U.S.-manufacturing agreement required under § 204 hasn’t been obtained, waived, or complied with. No federal agency has ever actually granted a march-in license, but the right has been formally petitioned for on several occasions (notably around prescription drug pricing), and in December 2023 NIST released a draft interagency guidance framework that would have allowed price to be weighed as one factor in a march-in determination; as of this writing that framework remains in draft form, unfinalized.
• U.S. manufacturing preference. Under 35 U.S.C. § 204, an exclusive license to sell or use the invention in the United States generally must require the licensee to manufacture substantially in the U.S. — a condition the funding agency can waive if the licensee shows domestic manufacturing isn’t commercially feasible or that reasonable efforts to secure a U.S. manufacturer failed.

Why it matters: the modern tech-transfer system

Congress’s own findings behind Bayh-Dole pointed to a federal patent portfolio that was overwhelmingly unlicensed and uncommercialized under the pre-1980 government-title default. Bayh-Dole’s uniform, ownership-retaining framework gave universities a predictable legal basis to patent and license inventions arising from federal grants — which is what made it commercially and legally sensible for research universities to build in-house technology transfer offices (TTOs) at scale starting in the 1980s. The Association of University Technology Managers (AUTM) and its annual licensing survey are the standard industry reference for tracking the resulting activity (invention disclosures, patents filed, licenses executed, startups formed) across U.S. research institutions. Nearly every downstream step in university IP commercialization — invention disclosure, provisional filing, exclusive or non-exclusive licensing, and industry-sponsored research agreements that touch federally funded IP — operates inside the compliance structure Bayh-Dole established.

Worked examples

• A university chemistry lab develops a novel catalyst while working under an NIH grant. The inventor discloses it to the university’s TTO, which files the disclosure in iEdison within the agency’s reporting window, elects to retain title within the two-year statutory period, and files a provisional patent application before the one-year bar under 35 U.S.C. § 102 runs. The university later grants an exclusive field-of-use license to a startup, which — absent a waiver — must manufacture the resulting product substantially in the United States under § 204. This entire sequence — disclosure, election, filing, licensing, manufacturing condition — is Bayh-Dole in operation.
• A small biotech company performing SBIR-funded research (see CASRAI’s SBIR entry) makes a subject invention under its federal award. The same disclosure-and-election framework applies to it as a small business under the statute, not only to universities — Bayh-Dole’s “contractor” category covers both.

Counter-example

A faculty member develops an invention entirely on personal time, using no university resources and no federal funding of any kind. Bayh-Dole does not apply to that invention at all, because there is no federal funding agreement in the chain; ownership is instead governed by the university’s own IP policy and applicable state law, not by 35 U.S.C. §§ 200–212. Likewise, an invention made under a purely industry-sponsored research agreement with no federal funding involved falls outside Bayh-Dole’s scope — though CASRAI’s industry-university partnerships guide covers how those agreements typically allocate IP rights instead.

Frequently asked questions

Does Bayh-Dole apply to all federally funded research?

Only where the funding took the form of a grant, contract, or cooperative agreement with a federal agency, and the recipient is a university, other nonprofit, or a small business. Large-business federal contractors are generally covered by equivalent policy (following a 1983 presidential memorandum) rather than by the statute’s own default text, and some categories of federal funding agreement fall outside the framework entirely.

Who owns a Bayh-Dole invention — the university or the individual inventor?

The statute gives the funding recipient institution (the “contractor”) the first right to elect title, not the individual inventor. Most U.S. research universities also require inventors to assign their rights to the institution under internal IP policy, so in practice the university (via its TTO) holds and manages title, subject to the inventor’s statutory right to share in any licensing income under § 202(c)(7)(B).

What happens if a university misses a Bayh-Dole deadline?

Missing the disclosure or election-of-title deadlines under 37 CFR § 401.14 can result in the government taking title to the invention, or acquiring the right to do so even where it doesn’t always exercise it. This is why timely iEdison reporting is treated as a compliance-critical process at most TTOs — see CASRAI’s iEdison guide for the exact deadline structure.

Has the government ever exercised march-in rights?

Not as of this writing. Several formal march-in petitions have been filed over the years, most visibly around prescription drug pricing, but no federal agency has granted a march-in license under 35 U.S.C. § 203. The scope and use of the right have been the subject of ongoing policy debate, including NIST’s December 2023 draft interagency framework addressing price as a possible march-in factor, which remained unfinalized as of this writing.